Scoop: Roche-backed start­up gives up on CD47, lays off all em­ploy­ees

Arch On­col­o­gy end­ed its work on de­vel­op­ing an an­ti-CD47 an­ti­body and most em­ploy­ees have left the com­pa­ny, End­points News has learned.

The Bris­bane, CA, and St. Louis biotech scrapped clin­i­cal de­vel­op­ment of the an­ti­body, dubbed AO-176, ac­cord­ing to an au­to­mat­ic re­ply email from a for­mer clin­i­cal op­er­a­tions di­rec­tor.

All Arch em­ploy­ees were let go and the com­pa­ny “was in a wind-down sit­u­a­tion,” ac­cord­ing to the LinkedIn bio of Arch’s for­mer VP of hu­man re­sources.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER